Clinical trial
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
NCT00003731 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00003731 |
|---|---|
| Title | Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors |
| Official title | First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 39 |
| Start date | Dec 1, 1998 |
| Primary completion | Jan 1, 2001 |
| First posted | May 20, 2004 |
| Last update posted | Sep 24, 2012 |
| Countries | Belgium, France, Germany, Italy, Netherlands, Portugal, Slovakia, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: